인문학
사회과학
자연과학
공학
의약학
농수해양학
예술체육학
복합학
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 저자정보
초록·키워드
The effects of IH901, a ginseng intestinal metabolite, on the antitumor activity and cardiotoxic adverse effect of doxorubicin were investigated in sarcoma-180 ascitic tumor-bearing mice. To evaluate the enhancing effect on the antitumor activity of doxorubicin, IH901 (50 ㎎/㎏) was orally administered for 28 days, in combination with intraperitoneal injection of doxorubicin (3 ㎎/㎏) on days 5, 12, 19 and 24, to mice intraperitoneally inoculated with 1 × 10? sarcoma-180 cells. The body weights of tumor-bearing mice dramatically increased from 10 days following tumor inoculation, leading to a mean survival time of 17.3 days. In contrast, such an increase in body weights induced by the ascitic tumor growth was markedly attenuated by doxorubicin (3 ㎎/㎏) administration, resulting in a long lifespan of 34.9 days. Interestingly, the body weight gain was further suppressed by the combination of IH901 (50 ㎎/㎏), leading to a normal feature. In addition, the mean survival time was extended by 129.3%, reaching 39.7 days, although IH901 was inactive alone. Separately, for the evaluation of protective effect on the cardiotoxicity of doxorubicin, IH901 (50 ㎎/㎏) was orally administered for 14 days, in combination with intraperitoneal injection of doxorubicin (5 ㎎/㎏) on days 5 and 9 to tumor-bearing mice. Although the heart weight of tumor-inoculated mice decreased to about 75% of normal, such an atrophy was remarkably recovered by coadministration of IH901. Furthermore, IH901 substantially reversed the dramatic decrease in mRNA of myocytic phospholipid hydroperoxide glutathione peroxidase, an antioxidant enzyme, as well as histopathological changes such as cytoplasmic vacuolization, mitochondrial swelling, and loss of myofibrils and intercalated disc induced by doxorubicin. Taken together, it is suggested that IH901 could be a potential adjunct for the potentiation of antitumor activity and reduction of cardiotoxicity of chemotherapeutic agents including doxorubicin.
본문·목차
인공지능 문자 인식 모델을 통해 추출된 텍스트로, 일부 오타나 오류가 포함될 수 있으나 지속적으로 개선 중입니다.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
최근 본 자료 전체보기
UCI(KEPA) : I410-ECN-0101-2009-510-016362156